The Quick Guide to Pain Management SOAP Note

Pain management documentation exists in a different regulatory universe than other clinical notes.

One poorly documented refill can trigger a DEA audit, a state board investigation, or even criminal prosecution.

I've spoken with pain management specialists and primary care physicians who are reducing or eliminating opioid prescribing entirely—not because their patients don't need pain control, but because the documentation burden and legal exposure feel impossible to manage.

The regulatory landscape has fundamentally changed over the past decade.

What used to be straightforward pain treatment now requires documented risk assessments, urine drug screens, controlled substance agreements, prescription monitoring database checks, functional improvement metrics, and detailed justification for every prescription decision.

Miss any of these elements and you're not just dealing with an insurance denial—you're potentially facing licensure issues or worse.

Your pain management SOAP notes need to demonstrate appropriate prescribing, diversion risk screening, and legitimate medical purpose for every controlled substance prescribed.

Let me show you exactly how to document pain management encounters in a way that protects both your patients and your license.

Why Pain Management Documentation Has Become So Complex

Pain management documentation requirements have exploded over the past 15 years in response to the opioid crisis.

Federal oversight has intensified: The DEA can and does audit prescribers. Your medical records must demonstrate legitimate medical purpose and usual course of professional practice for every controlled substance prescription.

State regulations vary widely: Some states mandate specific elements in pain management notes, require particular screening intervals, or limit opioid prescribing in ways that affect documentation.

Insurance companies scrutinize heavily: Prior authorizations for pain medications often require extensive documentation of failed alternative treatments, functional assessments, and risk mitigation strategies.

Medical boards investigate complaints: Inadequate documentation is one of the most common reasons physicians face disciplinary action related to controlled substance prescribing.

Malpractice risk is substantial: Both under-treatment and over-treatment of pain have led to successful lawsuits, with documentation being the deciding factor.

This means every pain management encounter needs documentation that addresses medical necessity, rules out drug-seeking behavior, demonstrates appropriate monitoring, and shows you're following evidence-based guidelines.

The Core Elements Required in Pain Management SOAP Notes

Effective pain management documentation goes far beyond recording a pain score and refilling medications.

Here's what your notes absolutely must include to meet regulatory and legal standards:

Pain Assessment Using Standard Metrics

Document pain intensity, location, quality, aggravating/relieving factors. Use standardized scales (0-10 numeric rating scale, functional pain scale).

Functional Impact Documentation

How does pain affect activities of daily living, work, sleep, mood? This demonstrates medical necessity and tracks treatment effectiveness.

Physical Examination Findings

Not just vital signs—document findings relevant to the pain complaint. This proves you examined the patient, not just refilled medications.

Review of Prescription Monitoring Database

Document that you checked your state's PDMP and what you found (or that you found nothing concerning). Many states legally require this.

Urine Drug Screen Results

For chronic opioid therapy, document UDS results and how you're interpreting unexpected findings (prescribed medications present, non-prescribed substances, absence of prescribed medications).

Assessment of "Four A's"

Analgesia (pain relief achieved), Activities of daily living (functional improvement), Adverse effects (side effects experienced), Aberrant behaviors (concerning drug-related behaviors).

Risk Assessment

Document screening for substance use disorder risk factors, mental health comorbidities, history of substance abuse, and current risk stratification.

Treatment Plan Rationale

Why are you prescribing this medication at this dose? What alternatives have failed? What are the treatment goals? When will you reassess?

Let me show you what this looks like in actual clinical scenarios.

Example 1: Chronic Low Back Pain, Established Patient on Opioid Therapy

Patient: 52-year-old male
Diagnosis: Chronic mechanical low back pain, L4-L5 degenerative disc disease
Medications: Oxycodone 10mg TID, gabapentin 600mg TID
Visit: Quarterly pain management follow-up

S – Subjective:

Patient presents for scheduled quarterly pain management visit. Reports chronic low back pain stable at baseline level of 5-6/10 at rest, 7-8/10 with prolonged standing or lifting. Current medication regimen providing adequate pain control allowing him to work modified duty as warehouse supervisor (no heavy lifting). Pain improves to 3-4/10 approximately 45 minutes after oxycodone dose, allowing 4-6 hours of improved function. Denies breakthrough pain episodes requiring additional medication. Sleep quality fair, wakes 2-3 times nightly to reposition but able to return to sleep. Mood stable on current antidepressant. Denies medication side effects including sedation, constipation managed with daily docusate. Medications stored in locked cabinet, no reports of lost or stolen medications. Obtained all prescriptions from this office only. Denies alcohol or illicit drug use. Compliant with controlled substance agreement terms.

O – Objective:

Vital Signs: BP 128/82, HR 74, RR 16, appears comfortable at rest
General: Alert, appropriate affect, no signs of intoxication or withdrawal
Back Exam: Lumbar paraspinal muscle tenderness bilaterally, ROM limited by pain (flexion 60°, extension 15°), negative straight leg raise, normal gait, normal strength lower extremities
Mood/Affect: Appropriate, engaged in conversation, no signs of depression or anxiety

Prescription Drug Monitoring Program (PDMP) Review: Checked state database today. Shows only prescriptions from this provider (oxycodone) and patient's psychiatrist (sertraline). No concerning patterns of early refills or multiple prescribers. Last check 3 months ago showed same pattern.

Urine Drug Screen: Collected today, immunoassay performed in office:

• Positive for oxycodone (prescribed, expected)
• Positive for gabapentin (prescribed, expected)
• Negative for non-prescribed opioids
• Negative for benzodiazepines
• Negative for amphetamines, cocaine, marijuana
• Creatinine: 145 mg/dL (normal range, valid specimen)

Controlled Substance Agreement: Current signed agreement on file, reviewed terms with patient, patient reports understanding and compliance.

Risk Stratification: Low risk based on Opioid Risk Tool (ORT score: 3). No aberrant behaviors observed or reported. Good social support, stable employment, psychiatric care established.

Functional Assessment:

• Pain interference with work: Moderate (able to work modified duty)
• Pain interference with sleep: Mild (occasional awakening)
• Pain interference with recreation: Moderate (limits hiking, previously enjoyed)
• Overall function: Stable compared to last visit, meeting treatment goals

A – Assessment:

Chronic mechanical low back pain secondary to degenerative disc disease, stable on current medication regimen. Patient demonstrating appropriate opioid therapy response with adequate analgesia (pain reduced from 8-9/10 to 5-6/10 baseline), maintained functional capacity (working modified duty), no adverse effects beyond manageable constipation, and no aberrant drug-related behaviors. PDMP and UDS results reassuring for appropriate medication use without diversion or concurrent substance abuse. Pain intensity and functional status unchanged from previous quarter, indicating stable chronic pain condition adequately managed on current regimen. Patient meets criteria for continued chronic opioid therapy per CDC guidelines: clear medical indication, benefits outweigh risks, appropriate monitoring in place.

P – Plan:

Medications:

• Continue oxycodone 10mg TID (90 tablets, 30-day supply). Prescription written for exactly 30 days, no early refills. Next refill date: [date 30 days out].
• Continue gabapentin 600mg TID
• Continue docusate 200mg daily for constipation prophylaxis
• Prescriptions entered into state PDMP

Non-Pharmacologic Treatment: Patient continues physical therapy home exercise program. Encouraged continued use of heating pad and maintaining activity within pain tolerance. Discussed weight loss goal to reduce mechanical load on spine (current BMI 29).

Monitoring Plan:

• Next urine drug screen in 3 months at quarterly visit
• PDMP check at each visit per state regulations
• Pain and functional assessment at each visit using standard tools
• Next appointment in 3 months (quarterly schedule appropriate for stable patient)

Patient Education: Reviewed safe opioid storage (locked cabinet), disposal of unused medications, risks of concurrent alcohol or benzodiazepine use, signs of developing tolerance requiring medical attention. Patient verbalized understanding. Reinforced that early refills will not be provided except for documented extraordinary circumstances (hospitalization, natural disaster).

Treatment Goals Review: Current goals remain: maintain pain at 5-6/10 or below, continue working modified duty, improve sleep quality, gradually increase recreational activity tolerance. Goals being partially met; will continue current approach.

Documentation of Medical Necessity: Opioid therapy continued based on: documented anatomical cause of pain (MRI-confirmed disc disease), failed conservative management including PT and NSAIDs (documented in previous notes), sustained functional improvement on current regimen, low risk profile, and appropriate monitoring showing no concerning behaviors or diversion.

---

Example 2: New Patient Consultation for Chronic Pain Management

Patient: 38-year-old female
Chief Complaint: Chronic neck pain following motor vehicle accident 2 years ago, requesting ongoing pain management
New Patient: Referred by primary care physician for pain specialty evaluation

S – Subjective:

Patient presents as new consultation for chronic cervical pain management. Rear-end MVA 2 years ago resulted in whiplash injury. Initially improved with PT and NSAIDs but pain persisted beyond 6 months. PCP prescribed hydrocodone/acetaminophen 5/325mg QID for past 18 months with partial relief. Reports current pain 6-7/10 baseline, located posterior neck radiating to right shoulder. Pain worsens with computer work (works as graphic designer), improves somewhat with rest and medication. Takes medication as prescribed, denies running out early. Previous treatments: PT (6 months, modest benefit), NSAIDs (ibuprofen caused gastritis), muscle relaxers (excessive sedation), cervical epidural injection (no benefit). Sleep disrupted by pain, wakes multiple times. Denies depression but reports frustration with chronic pain limiting activities. Denies history of substance abuse. Social alcohol use (1-2 drinks weekly). No tobacco or illicit drugs.

O – Objective:

Vital Signs: BP 118/76, HR 68, BMI 24
General: Well-appearing, no acute distress, appropriate behavior
Cervical Spine Exam: Tenderness bilateral cervical paraspinals C4-C6, ROM limited in all planes by pain (rotation 60° bilaterally, flexion/extension 50%), normal strength upper extremities, normal reflexes, negative Spurling's test
Imaging Review: Cervical MRI from 1 year ago reviewed - mild degenerative changes C5-C6, no significant stenosis or nerve root compression

PDMP Review: Checked state database. Shows hydrocodone prescriptions from PCP monthly for past 18 months, all appropriately timed. No other controlled substances. No red flags identified.

Urine Drug Screen: Collected and sent to lab for confirmation testing:

• Preliminary results: Positive for hydrocodone (expected), negative for other substances
• Confirmation testing pending, results will be reviewed before next visit

Screening Tools Administered:

• Opioid Risk Tool (ORT): Score 6 (moderate risk - family history of substance abuse, age 16-45, history of depression)
• Pain Catastrophizing Scale: Elevated score of 32 (indicates negative cognitive-emotional responses to pain)
• PHQ-9 Depression Screen: Score 12 (moderate depression)

Controlled Substance Agreement: Reviewed comprehensive agreement covering expectations, monitoring requirements, consequences of violations. Patient signed and received copy.

Previous Records Review: Records obtained from PCP document 18 months of stable opioid prescribing with no aberrant behaviors, multiple conservative treatment trials, and consistent pain complaints.

A – Assessment:

Chronic cervical pain syndrome following MVA with whiplash mechanism, now 2 years post-injury indicating chronic rather than acute condition. Imaging shows mild degenerative changes but not clearly correlating with symptom severity. Patient on long-term opioid therapy prescribed by PCP with adequate medication use behaviors (appropriate PDMP pattern, medication present on UDS, no early refills requested) but suboptimal pain control and emerging risk factors. Moderate-risk profile based on family substance abuse history and current depression symptoms requiring attention. Pain catastrophizing score suggests maladaptive cognitive patterns that may be limiting treatment response.

Current opioid regimen providing partial benefit but patient still significantly impaired functionally (work limitations, sleep disruption). Presents management dilemma: patient already on chronic opioid therapy with demonstrated appropriate use, but dose escalation concerning given moderate risk factors and comorbid depression.

P – Plan:

Comprehensive Pain Management Approach:

Medication Management:

• Continue hydrocodone/acetaminophen 5/325mg QID short-term (30-day supply) while establishing care and implementing multimodal plan
• Will NOT increase opioid dose at this time given moderate risk factors and need for optimization of adjuvant therapies
• Add duloxetine 30mg daily (dual indication: chronic pain and comorbid depression), titrate to 60mg after 1 week
• Trial topical diclofenac gel to cervical region for localized anti-inflammatory effect

Mental Health Integration:

• Referred to behavioral health for depression management and pain psychology (specifically cognitive-behavioral therapy for chronic pain)
• Depression treatment essential: pain outcomes poor when depression untreated
• Pain catastrophizing requires cognitive restructuring interventions

Physical Interventions:

• Referred to pain-specialized physical therapist for cervical stabilization program and postural training (relevant to computer work)
• Will consider repeat cervical epidural with different approach if other interventions fail
• Ergonomic assessment of workstation recommended

Monitoring Protocol Established:

• Urine drug screens: Random schedule, minimum quarterly, more frequent if concerns arise
• PDMP checks: Every visit without exception per state law
• Pill counts: Random unannounced counts may be requested
• Quarterly face-to-face visits minimum, no refills without examination
• Any violation of controlled substance agreement will result in discharge from pain management with appropriate tapering

Treatment Goals Defined (documented to measure progress):

1. Reduce pain from 6-7/10 to 4-5/10 or below
2. Eliminate sleep disruption from pain
3. Return to full work capacity without limitation
4. Resume recreational activities (specifically mentioned yoga, hiking)
5. Resolve depression symptoms (PHQ-9 less than 10)

Timeline: Reassess in 4 weeks. At that time will review depression treatment response, PT progress, UDS confirmation results. Future opioid prescribing contingent on: engagement with multimodal plan, improvement in functional metrics, no aberrant behaviors, and optimization of non-opioid therapies.

Patient Education: Extensive discussion regarding:

• Expectations for pain management (goal is improved function, not zero pain)
• Risks of long-term opioid therapy
• Importance of multimodal approach
• Consequences of agreement violations
• Safe storage and disposal Patient verbalized understanding and agreement with comprehensive treatment plan.

---

Example 3: Suspected Aberrant Behavior, Addressing Concerning Pattern

Patient: 29-year-old male
Diagnosis: Chronic pain post-lumbar fusion surgery
Concern: Early refill request, third time in 6 months
Visit: Unscheduled visit requesting early prescription

S – Subjective:

Patient presents requesting early refill of oxycodone 15mg QID, states he is out of medication 10 days before scheduled refill date. This is third early refill request in past 6 months (previously ran out early at 5 days and 7 days prior to refill date). Patient's explanation: "I've been in terrible pain, the medication isn't lasting as long, I think I need a higher dose." Denies taking extra doses intentionally. States he may have "accidentally double-dosed a few times" when pain was severe. Denies obtaining medications from other sources. When questioned about discrepancy, becomes defensive, states previous doctor "trusted him more" and "would just refill it." Reports pain has worsened to 8-9/10 despite being 7/10 at last visit one month ago.

O – Objective:

Vital Signs: BP 138/88, HR 88, pupils: 3mm reactive bilaterally (not constricted)
General: Appears anxious, agitated affect, minimal eye contact
Back Exam: Healed lumbar surgical scar, tenderness to palpation paraspinals (subjective, difficult to verify), normal gait observed entering room but exaggerated pain behaviors during directed examination

PDMP Review: Checked state database - CRITICAL FINDINGS:

• Shows oxycodone prescriptions from this office as expected
• ALSO shows hydrocodone prescription from ER physician 8 days ago (patient did not disclose)
• ALSO shows alprazolam prescription from different provider (psychiatry practice) started 2 months ago, not previously disclosed
• Pattern of multiple prescribers concerning for "doctor shopping"

Pill Count: Requested patient bring remaining oxycodone from current prescription. Patient states he "didn't bring them" and "doesn't have any left at home." Refusal to comply with pill count request.

Review of Records: ER visit 8 days ago documented chief complaint of "severe back pain" resulting in hydrocodone prescription for 12 tablets. Patient did not inform this office of ER visit.

Behavioral Observations:

• Inconsistent pain behaviors (normal gait observed, exaggerated during exam)
• Defensive/hostile when questioned
• Pressuring for specific medication and dose
• Non-compliance with treatment agreement (seeking controlled substances from multiple sources without disclosure)

A – Assessment:

Chronic post-surgical lumbar pain, however, current visit raises serious concerns for aberrant drug-related behaviors and possible opioid use disorder. Multiple red flags present:

Red Flags Identified:

1. Pattern of early refills (three occurrences in 6 months)
2. Doctor shopping behavior (ER visit for opioid prescription without disclosure)
3. Multiple controlled substance prescribers without disclosure (benzodiazepine from psychiatrist)
4. Escalating dose requests
5. Refusal to comply with pill count
6. Inconsistent pain presentation
7. Defensive, drug-seeking behaviors during visit

Differential considerations:

• Opioid use disorder with pseudo-addiction behaviors
• Undertreated pain with inadequate dose (less likely given behavioral patterns)
• Diversion (selling/sharing medications)
• Concurrent substance use disorder

Patient is in direct violation of controlled substance agreement which explicitly requires: disclosure of all controlled substances from any source, no early refills without documented emergency, compliance with pill counts when requested, and obtaining all opioid prescriptions from single provider.

Current situation represents both patient safety risk and prescriber liability risk. Cannot continue opioid prescribing without addressing concerning behaviors.

P – Plan:

Immediate Actions:

No early refill provided today. Explained that early refill violates controlled substance agreement and multiple prescriber pattern raises safety concerns. Patient strongly disagreed but explained this is non-negotiable.

Comprehensive UDS ordered: Sent to lab for confirmation testing to assess:

• Presence of prescribed oxycodone
• Presence of non-prescribed substances
• Presence of undisclosed medications (hydrocodone from ER, alprazolam) Patient initially refused, then agreed after explanation that continued prescribing requires UDS compliance.

Documented violations of controlled substance agreement:

1. Obtained opioid from ER without disclosure
2. Taking benzodiazepine concurrently without disclosure (dangerous combination)
3. Pattern of early refills indicating misuse
4. Refusal to comply with pill count

Next Steps Contingent on UDS Results and Patient Cooperation:

If UDS confirms opioid use disorder or diversion:

• Will initiate opioid taper with close monitoring
• Refer to addiction medicine for evaluation
• Will not continue long-term opioid therapy

If UDS shows prescribed medications only:

• Will continue prescribing but with intensified monitoring:
  • Weekly visits initially
  • Mandatory pill counts at each visit
  • Bridge prescriptions (7-day supplies instead of 30-day)
  • Required engagement with addiction psychiatry to address benzodiazepine use
  • Any further violations result in discharge with taper

Communication with Other Providers:

• Will contact ER to document this patient's pain management with this office
• Will contact psychiatrist regarding benzodiazepine prescribing and request coordination
• Documented in chart letter to patient outlining violations and conditions for continued care

Patient Education (documented for medicolegal protection): Patient informed that:

• Current behaviors concerning for medication misuse
• Opioids + benzodiazepines = dangerous combination, increased overdose risk
• Multiple prescribers = increased risk of adverse events
• Continued care requires strict adherence to agreement terms
• If unwilling to comply, will provide taper schedule and assistance finding alternative pain management

Patient became angry, stated "I'm in real pain, you're treating me like a drug addict." Empathetically explained that concern is patient safety and that patterns observed raise legitimate medical concerns requiring action. Offered pathways forward contingent on cooperation.

Follow-up: Patient to return in 3 days for UDS results discussion and determination of continued care. Given contact information for addiction resources. Documented this encounter thoroughly for medicolegal protection and consulted with clinic medical director regarding risk management approach.

---

Critical Documentation Requirements for Controlled Substance Prescribing

Based on regulatory guidance from the DEA, state medical boards, and CDC opioid prescribing guidelines, here are the non-negotiable elements your pain management notes must include:

Document Medical Necessity Every Visit

Why does this patient need controlled substances? Reference specific diagnosis, failed alternatives, functional goals being achieved.

PDMP Checks Must Be Documented

Note the date you checked, what you found (or didn't find), and how this influenced prescribing decisions.

Urine Drug Screen Results and Interpretation

Don't just file the lab result—document it in your note and explain unexpected findings. How did you address the patient who tests positive for non-prescribed substances?

Informed Consent Documentation

Document that you discussed risks, benefits, alternatives, and that patient consented to treatment. Controlled substance agreements should be referenced in notes.

Functional Improvement Metrics

Pain scores alone don't justify opioids. Document functional capacity: Can they work? Sleep? Perform ADLs? Are they improving?

Assessment of Aberrant Behaviors

Document any concerning behaviors observed (early refills, lost medications, multiple prescribers) and how you addressed them.

Risk Stratification

Use validated tools (Opioid Risk Tool, SOAPP-R) and document risk level. Higher-risk patients require more intensive monitoring.

Treatment Plan Justification

Why this medication at this dose? What's the treatment duration? When will you reassess? What are criteria for continuation versus discontinuation?

Red Flags That Require Documentation and Action

Certain patient behaviors or findings require specific documentation to protect yourself legally:

Early refill requests - Document exact dates, patient explanation, and your response (approved/denied with reasoning).

"Lost" or "stolen" medications - Document frequency, circumstances, police report (if claimed), and actions taken.

Multiple prescribers on PDMP - Document what you found, whether patient disclosed this, and how you addressed it.

Unexpected UDS results - Positive for non-prescribed substances or negative for prescribed medications both require documentation and clinical response.

Escalating dose requests - Document medical reasoning for any dose increases or why request was denied.

Inconsistent pain presentation - If examination findings don't match complaints, document specific observations objectively.

How Pain Management Documentation Differs by Setting

Different practice settings have different documentation priorities:

Primary Care: Focus on conservative management first, document failed alternatives before opioids, emphasize functional goals, integrate with management of other conditions.

Pain Specialty Practice: More detailed pain assessments, advanced interventional procedures documentation, multimodal treatment integration, higher-risk patient management.

Post-Surgical/Acute Pain: Clear connection to surgical procedure, expected duration of treatment, tapering plan, transition plan to non-opioid management.

Palliative/Cancer Pain: Different risk-benefit analysis, emphasis on quality of life and symptom control, less restrictive monitoring requirements in some states.

Streamlining Pain Management Documentation

Pain management notes require extensive documentation, but that doesn't mean you need to spend 30 minutes per note.

Here's how to maintain thoroughness while staying efficient:

Use structured templates that prompt for required elements (PDMP check, UDS results, functional assessment, risk screening).

Document monitoring activities as they happen rather than trying to recall details later.

Create standard language for common scenarios (stable patient on chronic therapy, addressing early refill request, documenting PDMP findings).

Integrate tools directly into workflow so screening instruments, UDS results, and PDMP checks automatically populate relevant note sections.

Or use soapnotes.doctor to record your pain management visit and generate comprehensive notes that include all required regulatory elements automatically.

You document the clinical encounter—the pain assessment, examination findings, patient behaviors, monitoring results—and the system ensures every required element is captured in a format that satisfies DEA requirements, state regulations, and insurance audits.

Final Thoughts on Pain Management Documentation

Pain management documentation has become one of the most complex and high-stakes areas of medical practice.

You're balancing patient care with regulatory compliance, managing legitimate pain while screening for substance use disorder, and creating documentation that serves clinical, legal, and administrative purposes simultaneously.

The key is systematic documentation that captures required elements every visit without exception.

PDMP checks, urine drug screens, functional assessments, risk evaluations, and treatment justification aren't optional extras—they're essential components of safe, legally defensible pain management.

Whether you're a pain specialist managing complex cases or a primary care provider prescribing occasional opioids, your documentation must demonstrate appropriate prescribing practices and patient monitoring.

Focus on objective findings, standardized tools, and clear reasoning for every prescribing decision. Document concerning behaviors without judgment but with specificity. Connect treatment to functional goals, not just pain scores.

These practices create notes that protect patients from inappropriate prescribing, protect you from regulatory action, and actually improve clinical outcomes through systematic assessment and monitoring.

---

Ready to streamline your pain management documentation while maintaining regulatory compliance?
Visit soapnotes.doctor and generate comprehensive pain management notes that include all required elements in minutes.